Patents Assigned to Lead Chemical Co., Ltd.
-
Patent number: 11491116Abstract: An adhesive patch comprising: a support; at least a pressure-sensitive adhesive layer provided on the support; and a release liner attached on the pressure-sensitive adhesive layer so as to cover the surface of the pressure-sensitive adhesive layer, in which the support is a 3D patterned sheet characterized in that a plurality of protruded lines and recessed lines parallelly and linearly extending are formed inside and outside lines in a plurality of figures partitioned by the lines, walls of the protruded lines and recessed lines in some of the figures are formed to be inclined by different inclination angles with respect to a base part, and the protruded lines have different heights from the base part, serving as physical parameters of the protruded lines and recessed lines, toward a predetermined direction in the sheet.Type: GrantFiled: March 16, 2016Date of Patent: November 8, 2022Assignee: LEAD CHEMICAL CO., LTD.Inventors: Takayasu Matsuzawa, Seijiro Yama, Naoki Murai
-
Publication number: 20190046464Abstract: An adhesive patch comprising: a support; at least a pressure-sensitive adhesive layer provided on the support; and a release liner attached on the pressure-sensitive adhesive layer so as to cover the surface of the pressure-sensitive adhesive layer, in which the support is a 3D patterned sheet characterized in that a plurality of protruded lines and recessed lines parallelly and linearly extending are formed inside and outside lines in a plurality of figures partitioned by the lines, walls of the protruded lines and recessed lines in some of the figures are formed to be inclined by different inclination angles with respect to a base part, and the protruded lines have different heights from the base part, serving as physical parameters of the protruded lines and recessed lines, toward a predetermined direction in the sheet.Type: ApplicationFiled: March 16, 2016Publication date: February 14, 2019Applicant: LEAD CHEMICAL CO., LTD.Inventors: Takayasu MATSUZAWA, Seijiro YAMA, Naoki MURAI
-
Patent number: 8841284Abstract: There is provided a novel compound having neurite-outgrowing activity that is useful for the prevention or the treatment of a neurodegenerative disease. A compound of Formula (I) [where X is OR or NR1R2, Y is OH, NR3R4, —NHC(?NH)NHR5, or —NHC(?NH)R5, and Z is a hydrogen atom, a linear or branched C1-5 alkyl group, or a 5- or 6-membered ring aryl group optionally having 1 or 2 nitrogen atom(s), sulfur atom(s), or oxygen atom(s)], or a pharmaceutically or veterinary-medically acceptable salt of the compound.Type: GrantFiled: July 21, 2009Date of Patent: September 23, 2014Assignee: Lead Chemical Co., LtdInventors: Hideo Nemoto, Yuji Matsuya
-
Patent number: 8568770Abstract: There is provided an adhesive preparation containing 5-methyl-1-phenyl-2-(1H)-pyridone. The adhesive preparation is a 5-methyl-1-phenyl-2-(1H)-pyridone-containing adhesive preparation including an active medicinal ingredient-containing layer, characterized in that the active medicinal ingredient-containing layer contains an lipophilic base, a dissolving agent (except glycerin and a medium-chain aliphatic acid triglyceride), and 5-methyl-1-phenyl-2-(1H)-pyridone or medically acceptable salts thereof.Type: GrantFiled: November 20, 2009Date of Patent: October 29, 2013Assignee: Lead Chemical Co., Ltd.Inventors: Takayasu Matsuzawa, Tamaki Horiuchi, Seijiro Yama, Sunao Takeuchi, Makoto Takeuchi
-
Patent number: 8551979Abstract: The present invention relates to nonaqueous preparation for percutaneous absorption prepared by laminating an adhesive layer comprising a nonsteroidal anti-inflammatory analgesic in an alkali metal salt form, and an inorganic acid which is strongly acidic compared with the nonsteroidal anti-inflammatory analgesic in a free form, together with a nonaqueous base, on a support. According to the present invention, drug-releasing characteristics and skin penetration in a nonaqueous preparation for percutaneous absorption can be improved because the addition of an inorganic acid in a nonaqueous base containing a drug in an alkali metal salt form leads to an improvement in the solubility of the drug in the base, and a good partitioning of the drug to skin surface. In addition, as the inorganic acid has no alcoholic hydroxy group in the structure, the inorganic acid does not react with the drug, therefore it causes no lowering in the stability of the drug by esterification.Type: GrantFiled: November 5, 2004Date of Patent: October 8, 2013Assignee: Lead Chemical Co., Ltd.Inventors: Seijirou Yama, Naoki Murai
-
Patent number: 8287900Abstract: There is provided a medicated patch including 5-methyl-1-phenyl-2-(1H)-pyridone. A medicated patch comprising a percutaneously absorbable preparation layer, wherein the percutaneously absorbable preparation layer includes 5-methyl-1-phenyl-2-(1H)-pyridone or a pharmaceutically acceptable salt thereof as an active component, a dissolving agent and an aqueous base material (or a rubber-type base material), and the active component is contained in an amount of 0.1 to 30 mass % relative to the total amount of the percutaneously absorbable preparation layer.Type: GrantFiled: May 26, 2008Date of Patent: October 16, 2012Assignees: Lead Chemical Co., Ltd., Shionogi & Co., Ltd.Inventors: Takayasu Matsuzawa, Tamaki Horiuchi, Seijiro Yama, Tetsukazu Hamamoto, Sunao Takeuchi, Daisuke Ichimatsu
-
Patent number: 8252273Abstract: There is provided an ultraviolet absorber having a strong absorptive capacity in the UVA range and an absorptive capacity in the UVB range to have an ultraviolet inhibitory effect in a wide range of wavelength, increasing in an ultraviolet absorptive capacity over the course of ultraviolet irradiation time in both the UVA and the UVB ranges and having an excellent solubility. An ultraviolet absorber comprising, as an active ingredient, a compound of General Formula I: (where —OA is an alkoxy group) that exhibits an ultraviolet A wave absorptive capacity which increases over time and that has an ultraviolet B wave absorptive capacity.Type: GrantFiled: April 2, 2008Date of Patent: August 28, 2012Assignee: Lead Chemical Co., Ltd.Inventors: Masao Mori, Haruo Saito
-
Publication number: 20120190841Abstract: There is provided a novel compound having neurite-outgrowing activity that is useful for the prevention or the treatment of a neurodegenerative disease. A compound of Formula (I) [where X is OR or NR1R2, Y is OH, NR3R4, —NHC(?NH)NHR5, or —NHC(?NH)R5, and Z is a hydrogen atom, a linear or branched C1-5 alkyl group, or a 5- or 6-membered ring aryl group optionally having 1 or 2 nitrogen atom(s), sulfur atom(s), or oxygen atom(s)], or a pharmaceutically or veterinary-medically acceptable salt of the compound.Type: ApplicationFiled: July 21, 2009Publication date: July 26, 2012Applicant: LEAD CHEMICAL CO., LTD.Inventors: Hideo Nemoto, Yuji Matsuya
-
Patent number: 8076368Abstract: A percutaneous absorption type cerebral protective agent containing as an active ingredient, 0.1 to 30 percent by mass of 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula: or a medically acceptable salt thereof in a base; a use of the compound as an active ingredient for the manufacture of a percutaneous absorption type pharmaceutical composition for protecting brain; and a method of protecting brain comprising administering to a patient the pharmaceutical composition as an active ingredient.Type: GrantFiled: November 12, 2003Date of Patent: December 13, 2011Assignee: Lead Chemical Co., Ltd,Inventors: Jun Mori, Tamaki Horiuchi, Seijiro Yama, Hitomi Waki, Shingo Shimada, Hitomi Hashitani
-
Publication number: 20110293670Abstract: There is provided an adhesive preparation containing 5-methyl-1-phenyl-2-(1H)-pyridone. The adhesive preparation is a 5-methyl-1-phenyl-2-(1H)-pyridone-containing adhesive preparation including an active medicinal ingredient-containing layer, characterized in that the active medicinal ingredient-containing layer contains an lipophilic base, a dissolving agent (except glycerin and a medium-chain aliphatic acid triglyceride), and 5-methyl-1-phenyl-2-(1H)-pyridone or medically acceptable salts thereof.Type: ApplicationFiled: November 20, 2009Publication date: December 1, 2011Applicants: SHIONOGI & CO., LTD., LEAD CHEMICAL CO., LTD.Inventors: Takayasu Matsuzawa, Tamaki Horiuchi, Seijiro Yama, Sunao Takeuchi, Makoto Takeuchi
-
Publication number: 20110021625Abstract: There is provided a neuronal cell death inhibitor having a high efficacy. A neuronal cell death inhibitor comprising a compound of general formula (1) below: (where R1 is a hydrogen atom or an optionally substituted hydroxy group; R2 is a hydrogen atom; R3 is a hydrogen atom or an optionally substituted hydroxy group; R4 is a hydrogen atom or an optionally substituted hydroxy group, R3 together with R4 is optionally an oxo group or a group of —O—(CH2)n—O— (where n is an integer of 2 to 4), or R2 together with R4 optionally forms an unsaturated bond between carbon atoms, the respective carbon atoms being attached to R2 and R4; R5 is a hydrogen atom or an optionally substituted lower alkyl group; each of R6, R7, and R8 is the same as or different from each other and is a hydrogen atom, an optionally substituted hydroxy group, an optionally substituted alkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group); or a salt thereof.Type: ApplicationFiled: January 23, 2009Publication date: January 27, 2011Applicant: LEAD CHEMICAL CO., LTD.Inventors: Hideo Nemoto, Chihiro Tohda, Yuji Matsuya
-
Publication number: 20100239508Abstract: There is provided an ultraviolet absorber having a strong absorptive capacity in the UVA range and an absorptive capacity in the UVB range to have an ultraviolet inhibitory effect in a wide range of wavelength, increasing in an ultraviolet absorptive capacity over the course of ultraviolet irradiation time in both the UVA and the UVB ranges and having an excellent solubility. An ultraviolet absorber comprising, as an active ingredient, a compound of General Formula I: (where —OA is an alkoxy group) that exhibits an ultraviolet A wave absorptive capacity which increases over time and that has an ultraviolet B wave absorptive capacity.Type: ApplicationFiled: April 2, 2008Publication date: September 23, 2010Applicant: LEAD CHEMICAL CO., LTD.Inventors: Masao Mori, Haruo Saito
-
Publication number: 20100119584Abstract: There is provided a medicated patch including 5-methyl-1-phenyl-2-(1H)-pyridone. A medicated patch comprising a percutaneously absorbable preparation layer, wherein the percutaneously absorbable preparation layer includes 5-methyl-1-phenyl-2-(1H)-pyridone or a pharmaceutically acceptable salt thereof as an active component, a dissolving agent and an aqueous base material (or a rubber-type base material), and the active component is contained in an amount of 0.1 to 30 mass % relative to the total amount of the percutaneously absorbable preparation layer.Type: ApplicationFiled: May 26, 2008Publication date: May 13, 2010Applicants: Lead Chemical Co., Ltd., Shionogi & Co., Ltd.Inventors: Takayasu Matsuzawa, Tamaki Horiuchi, Seijiro Yama, Tetsukazu Hamamoto, Sunao Takeuchi, Daisuke Ichimatsu
-
Patent number: 7662852Abstract: An antiviral preparation comprising as an active ingredient, a phorbol derivative of formula 1: wherein is R1 is —(CH2)aX(CH2)bCH3, —(CH2)cX(CH2)dYCH3, —CO(CH2)eCH3 or —(CH2)fCH3 R2 is —CO(CH2)nCH3, R3, R4 and R5 are hydrogen atom, or an aliphatic or aromatic carboxylic acid residue, X and Y are O or S, and each of a-f and n is a number, and having a specific safety index S.I.=CC50/EC50 of 10 or more wherein EC50 means a concentration at which HIV-1 induced cytopathogenic effect (CPE) in MT-4 cell is inhibited by 50%, and CC50 means a concentration at which survival of MT-4 cell in a cell proliferation test is reduced by 50%. These preparations are particularly effective for human immuno-deficiency virus (HIV).Type: GrantFiled: May 22, 2003Date of Patent: February 16, 2010Assignee: Lead Chemical Co., Ltd.Inventors: Masao Mori, Haruo Saito, Hideo Nemoto, Naoiki Yamamoto, Masao Hattori
-
Publication number: 20080113010Abstract: The present invention relates to nonaqueous preparation for percutaneous absorption prepared by laminating an adhesive layer comprising a nonsteroidal anti-inflammatory analgesic in an alkali metal salt form, and an inorganic acid which is strongly acidic compared with the nonsteroidal anti-inflammatory analgesic in a free form, together with a nonaqueous base, on a support. According to the present invention, drug-releasing characteristics and skin penetration in a nonaqueous preparation for percutaneous absorption can be improved because the addition of an inorganic acid in a nonaqueous base containing a drug in an alkali metal salt form leads to an improvement in the solubility of the drug in the base, and a good partitioning of the drug to skin surface. In addition, as the inorganic acid has no alcoholic hydroxy group in the structure, the inorganic acid does not react with the drug, therefore it causes no lowering in the stability of the drug by esterification.Type: ApplicationFiled: November 5, 2004Publication date: May 15, 2008Applicant: LEAD CHEMICAL CO., LTD.Inventors: Seijirou Yama, Naoki Murai
-
Patent number: 7361785Abstract: An ultraviolet ray protection agent including a compound having an ultraviolet ray protection effect as an active ingredient. The compound is expressed by general formula I?: wherein X represents NH or O; Y? represents a vinyl group substituted by a methyl group or a phenyl group, or a phenyl group substituted by a methoxy group or a fluorine atom, or a naphthyl group; and Z represents a phenyl group substituted by a methyl group, a carboxyl group or a nitro group, or a naphthyl group. The compound represented by the general formula I? includes both novel compounds of the present invention and known compounds. The ultraviolet ray protection agent of the present invention offers outstanding ultraviolet ray protection effectiveness and is very safe.Type: GrantFiled: November 5, 2002Date of Patent: April 22, 2008Assignee: Lead Chemical Co., Ltd.Inventors: Masao Mori, Haruo Saito, Masako Nakagawa, Atsushi Nishida
-
Patent number: 7265229Abstract: The present invention is a method for synthesizing macrosphelides represented by the following formula, and relates to the following method. The hydroxyl group of methyl 3-hydroxybutyrate is protected and reduced to alcohol. The alcohol is then oxidized to give 3-(tert-butyldimethylsilyloxy) butylaldehyde, and this aldehyde is then reacted with tert-butyl diethylphosphonoacetate to give an olefin, and then deprotected. Next, dehydrative condensation with diethylphosponoacetic acid are performed to give tert-butyl 5-[2-(diethylphosphonoyl) acetoxy] hex-2-enoate, and this compound is reacted with 3-(tert-butyldimethylsilyloxy) butylaldehyde to form a diester. Following this, deprotection is performed to give an alcohol, and dehydrative condensation of the alcohol with 3-(tert-butyldimethylsilyloxy) butyric acid gives a triester.Type: GrantFiled: November 26, 2002Date of Patent: September 4, 2007Assignee: Lead Chemical Co., Ltd.Inventors: Hideo Nemoto, Yu-ji Matsuya
-
Publication number: 20070148217Abstract: A percutaneous absorption type cow protective agent containing as an active ingredient, 0.Type: ApplicationFiled: November 12, 2003Publication date: June 28, 2007Applicant: LEAD CHEMICAL CO. LTD.Inventors: Jun Mori, Tamaki Horiuchi, Seijiro Yama, Hitomi Waki, Shingo Shimada, Hitomi Hashitani
-
Publication number: 20070066684Abstract: An antiviral preparation comprising as an active ingredient, a phorbol derivative of formula 1: wherein is R1 —(CH2)aX(CH2)bCH3, —(CH2)cX(CH2)dYCH3, —CO(CH2)eCH3 or —(CH2)fCH3 R2 is —CO(CH2)nCH3, R3, R4 and R5 are hydrogen atom, or an aliphatic or aromatic carboxylic acid residue, X and Y are O or S, and each of a-f and n is a number, and having a specific safety index S.I.=CC50/EC50 of 10 or more wherein EC50 means a concentration at which HIV-1 induced cytopathogenic effect (CPE) in MT-4 cell is inhibited by 50%, and CC50 means a concentration at which survival of MT-4 cell in a cell proliferation test is reduced by 50%. These preparations are particularly effective for human immuno-deficiency virus (HIV).Type: ApplicationFiled: May 22, 2003Publication date: March 22, 2007Applicant: Lead Chemical Co., Ltd.Inventors: Masao Mori, Haruo Saito, Hideo Nemoto, Naoiki Yamamoto, Masao Hattori
-
Patent number: 7164054Abstract: A liner for a patch used for covering the surface of a base agent layer of the patch may include a tear line portion for dividing and peeling the liner off the base agent layer is provided at a predetermined location. The thickness of the tear line portion may be made thinner than a generally average thickness of the liner. Therefore, when the patch is about to be used, the liner may easily be torn at the tear line portion and peeled off the base agent layer.Type: GrantFiled: June 12, 2002Date of Patent: January 16, 2007Assignee: Lead Chemical Co., Ltd.Inventors: Yoshiaki Mori, Haruo Saito